ClinicalTrials.gg
WithdrawnNCT06940804AVENTURINEUpdated Jul 2, 2025

A Clinical Study Investigating the Therapeutic Effects and Safety of an Investigational Cell Therapy Given With and Without an Additional Investigational Product in Males With Testicular Cancer or a Form of Cancer That Developed From Sperm

A Phase 2 interventional study of CLDN6 CAR-T and CLDN6 RNA-LPX in Testicular Germ Cell Tumor and Extragonadal Germ Cell Tumor, sponsored by BioNTech SE. Withdrawn. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-02.

Sponsored by BioNTech SE · Phase 2, Interventional, and Treatment

Why this study was withdrawn
Sponsor decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Study summary

This study is designed to evaluate the safety, efficacy, cellular kinetics, and immunogenicity of Claudin 6 (CLDN6) Chimeric antigen receptor T cell (CAR-T) ± CLDN6 ribonucleic acid-lipoplex (RNA-LPX) in participants born male with relapsed or refractory CLDN6-positive testicular or extragonadal germ cell tumors (GCTs) after prior salvage therapy.

Read the detailed description

The study will consist of two parts. The Safety Lead-in Part will evaluate safety and tolerability of CLDN6 CAR T ± CLDN6 RNA-LPX therapy in three arms with different dosing regimens. In the Safety Lead-in Part, participants will be randomized in a 1:1:1 ratio. Data from the Safety Lead-in Part up to the cut off will be used to select the dose for the single-arm Main Part of the study.

To increase the potency of the transferred CAR-T cells, a lymphodepleting chemotherapy regimen (comprising fludarabine and cyclophosphamide) will be administered in participants prior to infusion of CLDN6 CAR-T.

It is expected that it will take approximately 28 months for each participant to complete screening, apheresis, pre-treatment, treatment, and primary follow-up.

Participants who receive a CLDN6 CAR-T infusion will complete the long-term follow-up (LTFU) to assess safety and efficacy of the CLDN6 CAR-T treatment for a total of 15 years after CLDN6 CAR-T infusion. No investigational medicinal product (IMP) will be administered during the LTFU.

02

Conditions studied

  • Testicular Germ Cell Tumor
  • Extragonadal Germ Cell Tumor

Keywords

  • Advanced germ cell tumor
  • Metastatic germ cell tumors
  • CLDN6-positive relapsed or refractory advanced solid tumors
  • Salvage therapy
  • Testicular cancer
  • Immunotherapy
  • Autologous T-cells
03

In context

Testicular Germ Cell Tumor

85 studies on the registry are indexed under Testicular Germ Cell Tumor; 10 are open to participants now.

Browse Testicular Germ Cell Tumor studies →

Lead sponsor

BioNTech SE is the lead sponsor of 76 studies on the registry; 25 are open to participants now.

Of its 33 completed or terminated interventional studies of FDA-regulated products, 26 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Have a confirmed diagnosis of a testicular or extragonadal GCT of extracranial origin.
  • Evidence of by 1.1 or if RECIST 1.1 evaluation is not possible, elevation of serum tumor marker(s) (AFP or βhCG).
  • Participants with evidence of progressive or recurrent GCT defined as meeting at least one of the following criteria:

    • Tumor of new or growing or unresectable lesions demonstrating viable non-teratomatous GCT. In the event of an incomplete gross resection where viable GCT is found, participants will be considered eligible for this study.
    • Elevated serum tumor markers (AFP or ßhCG) that are increasing. Increase of an elevated lactate dehydrogenase alone does not constitute progressive disease.
    • Development of new or enlarging lesions in the setting of persistently elevated AFP or ßhCG, even if the markers are not continuing to rise.
  • Participants must have received prior high-dose chemotherapy with stem cell transplantation or conventional dose chemotherapy as salvage therapy. There is no maximum limit for the number of prior treatments.
  • Have a CLDN6-positive tumor assessed using an analytically validated immunohistochemistry assay at a central laboratory.
  • Have an performance status of 0 to 1.
  • Have laboratory tests of adequate organ function as defined in the protocol.

Key Exclusion Criteria:

  • Had major surgery within the 4 weeks before the first dose of study treatment.
  • Have received a prior CLDN6 CAR-T therapy.
  • Are receiving systemic (oral or IV) therapy >10 mg prednisolone daily, or its equivalent, for an underlying condition.
  • Have unresolved side effects of any prior therapy or procedures not recovered to version 5.0 Grade 1 or lower, except for AEs not constituting a safety risk by investigator judgment.
  • Have a pure teratoma, or pure teratoma with somatic-type or a combination of these histologies without any additional histologic subtype.
  • Have current evidence of active and/or uncontrolled brain or spinal metastases.
  • Have an active disease or any active immunologic disorder requiring with steroids or other immunosuppressive agents (protocol-defined exceptions apply). Note: Participants may be included if their disease is well controlled without the use of immunosuppressive agents, at the discretion of the investigator.
  • Have a history of another primary cancer within the 24 months prior to signing the main form (exceptions for definitely treated malignancies that have been in complete remission for more than 24 months apply).
  • Receipt of allogeneic stem cell transplantation in the 5 years prior to study enrollment.
  • Have cardiac conditions defined as exclusionary per protocol.
  • Have any concurrent conditions that could pose an undue medical hazard or interfere with the interpretation of the study results.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Safety Lead-in Part - CLDN6 CAR-T (dose level 1) + CLDN6 RNA-LPX

    Biological: CLDN6 CAR-T · Biological: CLDN6 RNA-LPX

  • Experimental
    Safety Lead-in Part - CLDN6 CAR-T (dose level 2)

    Biological: CLDN6 CAR-T

  • Experimental
    Safety Lead-in Part - CLDN6 CAR-T (dose level 2) + CLDN6 RNA-LPX

    Biological: CLDN6 CAR-T · Biological: CLDN6 RNA-LPX

  • Experimental
    Main Part - Selected dose of CLDN6 CAR-T + CLDN6 RNA-LPX

    Doses as selected from the Safety Lead-in Part

    Biological: CLDN6 CAR-T · Biological: CLDN6 RNA-LPX

Interventions

  • BiologicalCLDN6 CAR-T

    Intravenous (IV) infusion

  • BiologicalCLDN6 RNA-LPX

    IV injection

06

What researchers measure

Primary outcomes

  1. Safety Lead-in Part: Occurrence of treatment emergent adverse events (TEAEs) including Grade ≥3, adverse events of special interest (AESIs) and serious or fatal TEAEs by casual relationship to study treatment

    For each treatment arm

    Time frame: Up to 110 weeks after first dose of IMP

  2. Main Part: Overall response rate (ORR) assessed by the blinded independent central review (BICR)

    Defined as the percentage of participants in whom a confirmed complete response (CR) or partial response (PR) (per response evaluation criteria in solid tumors version 1.1 (\[RECIST 1.1\]) is observed as best overall response

    Time frame: Up to 110 weeks after first dose of IMP

  3. LTFU: Occurrence of AEs suspected to be related to CLDN6 CAR-T

    AEs may include: new malignancy (hematologic or solid) from genetically modified cells; new neurologic disorder, or exacerbation of a pre-existing disorder; new rheumatologic or autoimmune disorder, or exacerbation of a prior rheumatologic or other autoimmune disorder; new hematologic disorder; other new clinical condition considered by the investigator to be related to the prior genetically engineered T-cell therapy.

    Time frame: Up to 15 years after CLDN6 CAR-T administration

Secondary outcomes

  1. Safety Lead-in and Main Part: Occurrence of TEAEs including Grade ≥3, AESIs, and serious or fatal TEAEs by casual relationship to study treatment

    For each treatment arm

    Time frame: From first dose of IMP until 90 days after last dose of IMP, or until a new anticancer therapy is started, whichever occurs first

  2. Safety Lead-in and Main Part: Geometric mean of pharmacokinetic parameter maximum concentration (Cmax) of CLND6 CAR-T

    For each treatment arm using CLND6 CAR-T concentration in blood

    Time frame: Up to 97 weeks after first IMP dose

  3. Main Part: Geometric mean of pharmacokinetic parameter Cmax of interleukin (IL)-6

    From baseline until last available sample

    Time frame: Up to 97 weeks after first IMP dose

  4. Safety Lead-in and Main Part: Geometric mean of pharmacokinetic parameter time to maximum concentration (Tmax) of CLND6 CAR-T

    For each treatment arm using CLND6 CAR-T concentration in blood

    Time frame: Up to 97 weeks after first IMP dose

  5. Main Part: Geometric mean of pharmacokinetic parameter Tmax of IL-6

    From baseline until last available sample

    Time frame: Up to 97 weeks after first IMP dose

  6. Safety Lead-in and Main Part: Geometric mean of pharmacokinetic parameter area under the time concentration curve (AUC) of CLND6 CAR-T

    For each treatment arm using CLND6 CAR-T concentration in blood

    Time frame: Up to 97 weeks after first IMP dose

  7. Safety Lead-in and Main Part: Overall response rate (ORR) assessed by the investigator

    Defined as the percentage of participants in whom a confirmed complete response (CR) or partial response (PR) is observed as best overall response. Tumor response will be assessed by the investigator per RECIST 1.1. In the Safety Lead-in Part, tumor assessment will also be made based on reduction of the serum tumor marker(s) (alpha fetoprotein \[AFP\]/beta human chorionic gonadotropin \[βhCG\]).

    Time frame: Up to 110 weeks after first dose of IMP

  8. Safety Lead-in and Main Part: Disease control rate (DCR) assessed by the investigator

    Defined as the percentage of participants in whom a CR, PR, or stable disease (SD) is observed as best overall response. Tumor response will be assessed per RECIST 1.1. In the Safety Lead-in Part, tumor assessment will also be made based on reduction of the serum tumor marker(s) (alpha fetoprotein \[AFP\]/beta human chorionic gonadotropin \[βhCG\]).

    Time frame: Up to 110 weeks after first dose of IMP

  9. Main Part: DCR assessed by BICR

    Defined as the percentage of participants in whom a CR, PR, or SD is observed as best overall response. Tumor response will be assessed per RECIST 1.1

    Time frame: Up to 110 weeks after first dose of IMP

  10. Main Part: Progression-free survival (PFS) assessed by the investigator

    Defined as the time from first dose of CLDN6 CAR-T to progressive disease (PD) or death from any cause, whichever occurs first. Tumor response will be assessed per RECIST 1.1

    Time frame: Up to 110 weeks after first dose of IMP

  11. Main Part: PFS assessed by BICR

    Defined as the time from first dose of CLDN6 CAR-T to PD or death from any cause, whichever occurs first. Tumor response will be assessed per RECIST 1.1

    Time frame: Up to 110 weeks after first dose of IMP

  12. LTFU: PFS assessed by the investigator

    Defined as the time from first dose of CLDN6 CAR-T to first objective progressive disease per RECIST 1.1 and/or based on reduction of the serum tumor marker(s) (AFP/βhCG), or death from any cause, whichever occurs first.

    Time frame: Up to 15 years after the last IMP administration

  13. Main Part: Duration of response (DOR) assessed by the investigator

    Defined as the time from first objective response (CR or PR) to first occurrence of tumor progression, or death from any cause, whichever occurs first. Tumor response will be assessed per RECIST 1.1.

    Time frame: Up to 110 weeks after first dose of IMP

  14. Main Part: DOR assessed by BICR

    Defined as the time from first objective response (CR or PR) to first occurrence of tumor progression, or death from any cause, whichever occurs first. Tumor response will be assessed per RECIST 1.1.

    Time frame: Up to 110 weeks after first dose of IMP

  15. Main Part: Overall survival (OS)

    Defined as the time from first dose of CLDN6 CAR-T to death from any cause

    Time frame: Up to 97 weeks after first dose of IMP or until death, whichever occurs first

  16. LTFU: OS

    Defined as the time from first dose of CLDN6 CAR-T to death from any cause

    Time frame: Up to 15 years from last genetically engineered T-cell infusion or until death, whichever occurs first

  17. Main Part: Percentage of participants with pre-existing anti-chimeric antigen receptor (CAR) antibodies prior to CLDN6 CAR-T infusion

    For each treatment arm using CLND6 CAR-T concentration in blood and of IL-6 from baseline until last available sample

    Time frame: On Day 1 prior to CAR-T infusion

  18. Main Part: Percentage of participants with treatment-emergent anti-CAR antibodies post-CLDN6 CAR-T infusion until last available sample

    Anti-CAR antibodies including both treatment-induced and treatment-boosted

    Time frame: Up to 97 weeks after first dose of IMP

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2025; primary completion for Jun 2042, 203 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2025
First posted
Apr 23, 2025
StartEst.
Jul 2025
Primary completionEst.
Jun 2042
CompletionEst.
Jun 2042
Last update
Jul 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06940804
Lead sponsor
BioNTech SE
Responsible party
Sponsor
First posted
Apr 23, 2025
Start date
Jul 2025 (estimated)
Primary completion
Jun 2042 (estimated)
Completion
Jun 2042 (estimated)
Last update
Jul 2, 2025

Study contacts

BioNTech Responsible Person
study director · BioNTech SE

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion